NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
GENOMIC HEALTH, INC.Condensed Consolidated Statements of Income(In thousands, except per share amounts)Three Months EndedTwelve Months EndedDecember 31,December 31,2012201120122011UnauditedUnauditedREVENUES:Product revenues$
204,766Contract revenues4302421,7161,345Total revenues60,42853,397235,173206,111OPERATING EXPENSES (1):Cost of product revenues9,6417,35237,01833,832Research and development13,32910,28249,10439,864Selling and marketing23,89622,39393,55383,613General and administrative11,54610,63847,06440,543Total operating expenses58,41250,665226,739197,852Income from operations2,0152,7328,4348,259Interest income704295221Other income (expense), net54(14)(58)(205)Income before income taxes2,1392,7228,6718,275Income tax expense187163422429Net income$
7,846Basic net income per share$
0.27Diluted net income per share$
0.26Shares used in computing basic net income per share30,60229,64430,32629,395Shares used in computing diluted net income per share32,30831,06232,15130,754
Included in operating expenses for the three months ended December 31, 2012 were non-cash charges of $5.8 million, including $4.3 million of stock-based compensation expense and $1.5 million of depreciation and amortization expenses
|SOURCE Genomic Health, Inc.|
Copyright©2012 PR Newswire.
All rights reserved